Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Palatin Starts Phase 2 Study of Bremelanotide with Tirzepatide for Obesity
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Brand Name : Vyleesi
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 22, 2024
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bremelanotide Acetate,Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Palatin Initiates Phase 2 Study of Bremelanotide for Erectile Dysfunction
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with PDE5i for the treatment of erectile dysfunction.
Brand Name : Vyleesi
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 20, 2024
Lead Product(s) : Bremelanotide Acetate,Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Brand Name : Vyleesi
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 12, 2024
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Palatin Receives FDA Clearance for Bremelanotide with Tirzepatide in Obesity Treatment
Details : PT-141 (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for the treatment of obesity.
Brand Name : PT-141
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 02, 2024
Lead Product(s) : Bremelanotide Acetate,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Acquisition
Cosette Pharmaceuticals Acquires Vyleesi® from Palatin Technologies
Details : Cosette expands its women's health platform by acquiring Vyleesi (bremelanotide acetate), first as-needed treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder.
Brand Name : Vyleesi
Molecule Type : Peptide
Upfront Cash : $12.0 million
January 03, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Acquisition
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Divestment
Palatin Completes Sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
Details : Cosette expands its women's health platform through divestment by adding Vyleesi, the first approved as-needed treatment for premenopausal women with acquired hypoactive sexual desire disorder.
Brand Name : Vyleesi
Molecule Type : Peptide
Upfront Cash : $12.0 million
January 02, 2024
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Divestment
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Divestment
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Details : Through the divestment, Cosette will further expand its women's health platform by adding Vyleesi (bremelanotide acetate), the first and only as-needed treatment approved for premenopausal women with acquired, generalized hypoactive sexual desire disorde...
Brand Name : Vyleesi
Molecule Type : Peptide
Upfront Cash : $12.0 million
December 20, 2023
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Cosette Pharma
Deal Size : $171.0 million
Deal Type : Divestment
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Brand Name : Vyleesi
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 10, 2023
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Sponsor : Fosun Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vyleesi (bremelanotide injection) is a melanocortin receptor (MCR) agonist that is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Brand Name : Vyleesi
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 08, 2023
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Sponsor : Fosun Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BMT-701 (bremelanotide) is a synthetic peptide analogue of melanocyte stimulating hormone alpha (MSHα), and its metabolism is by hydrolysis of amide bonds and digestion by cellular peptidases.
Brand Name : BMT-701
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 19, 2023
Lead Product(s) : Bremelanotide Acetate
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?